Abnormally high HIP1 expression is associated with metastatic behaviors and poor prognosis in ESCC

Sun,Ying; Zhou,Yongan; Xia,Jinghua; Wen,Miaomiao; Wang,Xuejiao; Zhang,Jiao; Zhang,Yanning; Zhang,Zhipei; Jiang,Tao

doi:10.3892/ol.2020.12340

Abnormally high HIP1 expression is associated with metastatic behaviors and poor prognosis in ESCC

Authors:
- Ying Sun
- Yongan Zhou
- Jinghua Xia
- Miaomiao Wen
- Xuejiao Wang
- Jiao Zhang
- Yanning Zhang
- Zhipei Zhang
- Tao Jiang
View Affiliations

Affiliations: Department of Thoracic Surgery, Second Affiliated Hospital of Air Force Medical University, Xi'an, Shaanxi 710038, P.R. China
Published online on: November 30, 2020 https://doi.org/10.3892/ol.2020.12340
Article Number: 79
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Huntingtin interacting protein 1 (HIP1) is overexpressed in several human malignancies. However, the biological function of HIP1 in esophageal squamous cell carcinoma (ESCC), and its effect on the prognosis of patients remain unclear. The present study aimed to investigate HIP1 expression in ESCC via immunohistochemistry, reverse transcription‑quantitative PCR and western blot analyses. The association between HIP1 expression and the clinicopathological characteristics of 173 patients with ESCC was statistically analyzed. The effect of HIP1 expression on patient prognosis was assessed via Kaplan‑Meier and Cox regression analyses. Lentivirus‑delivered RNA interfering technique was used to overexpress and downregulate HIP1 expression in ESCC cell lines. The results demonstrated that HIP1 expression was significantly higher in ESCC tissues compared with adjacent normal tissues, and HIP1 expression was associated with histological differentiation, tumor‑node‑metastasis stage and lymph node metastasis. Furthermore, the overall survival time of patients with high HIP1 expression was significantly shorter than those with low HIP1 expression. Cellular mobility demonstrated that overexpressing HIP1 increased ESCC proliferation, migration and invasion, whereas silencing HIP1 decreased ESCC proliferation, migration and invasion. Furthermore, overexpressing HIP1 induced ESCC cells to enter the S and G2 phases from the G1 phase, whereas HIP1 knockdown arrested the cell cycle in the G1 phase. Taken together, the results of the present study suggest that HIP1 is associated with proliferation and metastatic behaviors in ESCC, and thus may be used as a potential prognostic indicator for patients with ESCC.

View Figures

View References

1	Lee YT, Tan YJ and Oon CE: Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 834:188–196. 2018. View Article : Google Scholar
2	da Cunha Santos G, Shepherd FA and Tsao MS: EGFR mutations and lung cancer. Annu Rev Pathol. 6:49–69. 2011. View Article : Google Scholar
3	Mahtani R, Holmes FA, Badve S, Caldera H, Coleman R, Mamounas E, Kalinsky K, Kittaneh M, Lower E, Pegram M, et al: A roundtable discussion of the breast cancer therapy expert group (BCTEG): Clinical developments and practice guidance on human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Clin Breast Cancer. 20:e251–e260. 2020. View Article : Google Scholar
4	Zhang L, Wang H, Li W, Zhong J, Yu R, Huang X, Wang H, Tan Z, Wang J and Zhang Y: Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis. Oncotarget. 8:3289–3303. 2017. View Article : Google Scholar
5	Kalchman MA, Koide HB, McCutcheon K, Graham RK, Nichol K, Nishiyama K, Kazemi-Esfarjani P, Lynn FC, Wellington C, Metzler M, et al: HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. Nat Genet. 16:44–53. 1997. View Article : Google Scholar
6	Waelter S, Scherzinger E, Hasenbank R, Nordhoff E, Lurz R, Goehler H, Gauss C, Sathasivam K, Bates GP, Lehrach H and Wanker EE: The huntingtin interacting protein HIP1 is a clathrin and alpha-adaptin-binding protein involved in receptor-mediatendocytosis. Hum Mol Genet. 10:1807–1817. 2001. View Article : Google Scholar
7	Metzler M, Legendre-Guillemin V, Gan L, Chopra V, Kwok A, McPherson PS and Hayden MR: HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2. J Biol Chem. 276:39271–39276. 2001. View Article : Google Scholar
8	Gottfried I, Ehrlich M and Ashery U: HIP1 exhibits an early recruitment and a late stage function in the maturation of coated pits. Cell Mol Life Sci. 66:2897–2911. 2009. View Article : Google Scholar
9	Bradley SV, Smith MR, Hyun TS, Lucas PC, Li L, Antonuk D, Joshi I, Jin F and Ross TS: Aberrant Huntingtin interacting protein 1 in lymphoid malignancies. Cancer Res. 67:8923–8931. 2007. View Article : Google Scholar
10	Marghalani S, Feller JK, Mahalingam M and Mirzabeigi M: Huntingtin interacting protein 1 as a histopathologic adjunct in the diagnosis of merkel cell carcinoma. Int J Dermatol. 54:640–647. 2015. View Article : Google Scholar
11	Rao DS, Hyun TS, Kumar PD, Mizukami IF, Rubin MA, Lucas PC, Sanda MG and Ross TS: Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. J Clin Invest. 110:351–360. 2002. View Article : Google Scholar
12	Sun Y, Han Y, Wang X, Wang W, Wang X, Wen M, Xia J, Xing H, Li X and Zhang Z: Correlation of EGFR Del 19 with Fn14/JAK/STAT signaling molecules in non-small cell lung cancer. Oncol Rep. 36:1030–1040. 2016. View Article : Google Scholar
13	Zhao J, Zhou Y, Zhang Z, Tian F, Ma N, Liu T, Gu Z and Wang Y: Upregulated fascin1 in non-small cell lung cancer promotes the migration and invasiveness, but not proliferation. Cancer Lett. 290:238–247. 2010. View Article : Google Scholar
14	Wang WP, Sun Y, Lu Q, Zhao JB, Wang XJ, Chen Z, Ni YF, Wang JZ, Han Y, Zhang ZP, et al: Gankyrin promotes epithelial-mesenchymal transition and metastasis in NSCLC through forming a closed circle with IL-6/STAT3 and TGF-β/SMAD3 signaling pathway. Oncotarget. 8:5909–5923. 2017. View Article : Google Scholar
15	Liu T, Li WM, Wang WP, Sun Y, Ni YF, Xing H, Xia JH, Wang XJ, Zhang ZP and Li XF: Inhibiting CREPT reduces the proliferation and migration of non-small cell lung cancer cells by down-regulating cell cycle related protein. Am J Transl Res. 8:2097–2113. 2016.
16	Liang CC, Park AY and Guan JL: In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2:329–333. 2007. View Article : Google Scholar
17	Donohoe CL and Phillips AW: Cancer of the esophagus and esophagogastric junction: An 8th edition staging primer. J Thorac Dis. 9:E282–E284. 2017. View Article : Google Scholar
18	Ross TS, Bernard OA, Berger R and Gilliland DG: Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood. 91:4419–4426. 1998. View Article : Google Scholar
19	Hong M, Kim RN, Song JY, Choi SJ, Oh E, Lira ME, Mao M, Takeuchi K, Han J, Kim J and Choi YL: HIP1-ALK, a novel fusion protein identified in lung adenocarcinoma. J Thorac Oncol. 9:419–422. 2014. View Article : Google Scholar
20	Wang J, Yu M, Guo Q, Ma Q, Hu C, Ma Z, Yin X, Li X, Wang Y, Pan H, et al: Prognostic significance of huntingtin interacting protein 1 expression on patients with acute myeloid leukemia. Sci Rep. 7:459602017. View Article : Google Scholar
21	Hsu CY, Lin CH, Jan YH, Su CY, Yao YC, Cheng HC, Hsu TI, Wang PS, Su WP, Yang CJ, et al: Huntingtin-interacting protein-1 is an early-stage prognostic biomarker of lung adenocarcinoma and suppresses metastasis via Akt-mediated epithelial-mesenchymal transition. Am J Respir Crit Care Med. 193:869–880. 2016. View Article : Google Scholar